H2Mab-139
H2Mab-139 (H2Mab-141;H2Mab-19) is an anti-HER2 monoclonal antibody. H2Mab-139 specifically binds to HER2 on various cancer cells. H2Mab-139 can detect HER2 overexpression in colorectal cancer via flow cytometry and immunohistochemical analysis. H2Mab-139 exhibits anti-tumor activity in mouse oral cancer and breast cancer xenografts. H2Mab-139 is applicable to research related to multiple cancers including colon cancer, oral cancer, and breast cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- 순도&문서
- References
-
Help & FAQs
All EGFR Isoforms
More
Biological Activity
Human
H2Mab-139 (10 μg/mL; 30 min at 4°C) specifically binds to HER2 on LN229/HER2 glioblastoma cells and the colorectal cancer cell lines Caco-2, HCT-116, HCT-15, HT-29, LS 174T, COLO 201, COLO 205, HCT-8, SW1116, and DLD-1 in flow cytometry assays[1].
H2Mab-139 (10 μg/mL) specifically detects HER2 protein with a molecular weight of approximately 200 kDa in LN229/HER2 glioblastoma cell lysates via Western blotting[1].
H2Mab-139 (10 μg/mL; 1 h at room temperature) specifically stains the cell membrane of HER2-positive human colon cancer tissue sections in immunohistochemical assays[1].
H2Mab-19 (6 ng/mL to 100 μg/mL) maintains high binding affinity for HER2 in HER2-expressing BT-474, HSC-2, and SAS cell lines, with Kd values of 2.3 × 10-8 M, 9.5 × 10-9 M, and 5.5 × 10-9 M, respectively[2].
H2Mab-19 (5 h at 37°C) exhibits high CDC activity against BT-474, HSC-2 and SAS cell lines, with cytotoxicity rates of 46%, 51% and 53%, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
H2Mab-19 (100 μg per dose; i.p.; on days 1, 6, and 14 after cell implantation) significantly reduces tumor development and tumor weight in HSC-2 oral cancer xenografts[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 10 weeks old, purchased at 6 weeks old) BT-474 cells (1.33x108) [2]
-
Dosage:100 μg per dose
-
Administration:i.p.; on days 1, 7, and 14 after cell implantation
-
Result:Significantly reduced tumor development compared to controls on days 5, 7, 12, 15, and 18 post-implantation.
Significantly reduced tumor weights compared to control mice.
Showed no significant difference in total body weight compared to control mice.
-
Animal Model:BALB/c nude (female, 10 weeks old, purchased at 6 weeks old) HSC-2 or SAS cell (1.33x108)[2]
-
Dosage:100 μg per dose
-
Administration:i.p.; on days 1, 6, and 14 after cell implantation
-
Result:Significantly reduced tumor development compared to controls on days 6, 10, 14, 17, and 20 post-implantation.
Significantly reduced tumor weights compared to control mice.
Showed no significant difference in total body weight compared to control mice.\nSignificantly reduced tumor development compared to controls on days 14, 17, and 20 post-implantation.
Significantly reduced tumor weights compared to control mice.
Showed no significant difference in total body weight compared to control mice.
ERBB2/HER2/CD340
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[H2Mab-139]
-
Synonyms
H2Mab-141, H2Mab-19
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
[1]. Kaneko MK, et al. Development of an Anti-HER2 Monoclonal Antibody H2Mab-139 Against Colon Cancer. Monoclon Antib Immunodiagn Immunother. 2018;37(1):59-62. [Content Brief]
[2]. Takei J, et al. H2Mab-19, an anti-human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts. Exp Ther Med. 2020;20(2):846-853. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
H2Mab-139 Related Classifications
HY-P991980 Related Classifications
Powered by Bioz